Business description
With a focus on transformative medicines in oncology, rare disease and neuroscience, our vision is to be a leading global mid-size biopharmaceutical company. With the right combination of size and agility, we continue to push ourselves as a business and as individuals to deliver positive change.
Management board & Supervisory board
| CEO |
| David Loew |
| Management board |
| Yan Moore M.D., Aymeric Le Chatelier, Aidan Murphy Ph.D., Craig Marks, Francois Garnier, Gwenan White, Regis Mulot, Dominique Bery, Alexander McEwan |
| Supervisory board |
| - |
Company data
| Name: |
Ipsen SA |
| Address: |
65, quai Georges Gorse,65, quai Georges Gorse Boulogne-Billancourt 92100 |
| Phone: |
+33 1 58 33 50 00 |
| Fax: |
- |
| E-mail: |
-
|
| Internet: |
https://www.ipsen.com |
| Industry: |
Biotechnology |
| Sector: |
Biotechnology |
| Sub sector: |
Biotechnology |
| End of financial year: |
31/12 |
| Free Float: |
41.52% |
| IPO date: |
01/12/2005 |
Investor relations
| Name: |
Craig Marks |
| IR phone: |
+44 7584 349 193 |
| IR Fax: |
- |
| IR e-mail: |
-
|
